Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060Phase 2Active Not Recruiting6452 enrolled

Biomarker Guided Treatment in Gynaecological Cancer

NCT02543710Phase 4Recruiting1300 enrolled

Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia

NCT02872818Phase 4Completed40 enrolled

View all 43 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

NCU-37 alleviates leuprorelin-induced perimenopausal syndrome in infertile women by modulating the gut microbiota: a randomized controlled trial.

Wu Xiaoyun, Chen Weijun, Yong Qianyu et al. · Food Funct · 2026

PMID: 41399984RCT

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.

Ohashi Yasuo, Shiba Eiichi, Yamashita Hiroko et al. · Support Care Cancer · 2018

PMID: 29063390RCTFull text (PMC)

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study.

Harada Tasuku, Osuga Yutaka, Suzuki Yusuke et al. · Fertil Steril · 2022

PMID: 34895700Trial

Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.

Jeong Jae Ho, Kim Jeong Eun, Ahn Jin-Hee et al. · Eur J Cancer · 2021

PMID: 33388491Trial

An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children.

Luo Xiaoping, Hou Ling, Zhong Yan et al. · Medicine (Baltimore) · 2021

PMID: 34941067TrialFull text (PMC)

Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.

Osuga Yutaka, Nakano Yasuaki, Yamauchi Yuji et al. · Fertil Steril · 2021

PMID: 33715871Trial

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study.

Kurebayashi Junichi, Toyama Tatsuya, Sumino Shuuji et al. · Breast Cancer · 2017

PMID: 27017207TrialFull text (PMC)

Anastrozole plus leuprorelin in early maturing girls with compromised growth: the "GAIL" study.

Papadimitriou D T, Dermitzaki E, Papagianni M et al. · J Endocrinol Invest · 2016

PMID: 26507391TrialFull text (PMC)

Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.

Suzuki Kazuhiro, Namiki Mikio, Fujimoto Tsukasa et al. · Jpn J Clin Oncol · 2015

PMID: 26486824TrialFull text (PMC)

Is high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial.

Lee Seung-Hwan, Lee Hyun-Moo, Kim Sae-Woong et al. · Yonsei Med J · 2014

PMID: 24532497TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

Urology

Health Goals

Goals connected through associated conditions

Support Prostate Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Leuprorelin (substance)
SNOMED CT: 397198002
UMLS CUI: C0085272
RxNorm CUI: 42375

Clinical Data

This intervention maps to 12 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.